Cellular Dynamics International (CDI) is a global leader in iPS cell technology and the world's largest producer of terminally differentiated human cells derived from iPS cells. Unlike embryonic stem cells, which are derived from early stage embryos, iPS cells are generated by reprogramming adult cells (e.g. skin, blood) to become stem cells capable of differentiation into any cell type in the body. Importantly, iPS cell technology uniquely provides access to any cell type from any individual, ethnic, or patient population, which will enable powerful new strategies for drug development and personalized medicine.
CDI's iCell products are highly pure human iPS cell-derived cells that exhibit expected characteristics and functions, remaining viable in culture for weeks to facilitate reproducible, acute and longer term studies. Because they recapitulate in vivo cellular behavior, these cells overcome the limitations of cadaveric, immortalized cell line, and animal models to advance life science, drug discovery, and biomedical research.
In addition to its portfolio of iCell products (i.e. cardiomyocytes, neurons, endothelial cells, hepatocytes), CDI offers MyCell Services to enable the manufacture of iPS cells and terminally differentiated cells from the customer’s donor samples.